Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud. You can reach Allison on Signal at AllisonDeAngelis.01. Good morning, Pharmalittle readers. This is Allison DeAngelis, filling in for Mr. Pharmalot. Today’s newsletter…
The continued effort by drug manufacturers and PBMs to conceal net drug prices reveals a system designed to protect profits, not patients. While transparency laws exist, loopholes and regulatory rollbacks allow the industry to maintain secrecy. The result is higher out-of-pocket costs, confusion, and real harm to patients who cannot access or afford the medicines…
Good morning, Jason Mast here filing in for Ed on this Christmas week. No coffee this morning — well, not yet — but rather some Yemeni Tea from a certain rapidly expanding New York haunt. It’s sweeter than my usual cup and warmer. Ten out of ten. Anyway, here’s some news for you today. I…
NPPA Bars Pricing of Loose Drugs Above Pro-Rata MRP Under DPCO, Parliament Informed We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
WASHINGTON — Nine drugmakers on Friday are set to unveil deals with the Trump administration to lower the prices of some of their drugs, marking the administration’s largest such deal to date. The deals are the latest in a series of agreements with drugmakers that are aimed at lowering prices to levels paid by peer…
The UK government has confirmed that the rebate rate for newer medicines supplied to the NHS under the Voluntary Scheme for Branded Medicines Pricing and Access (VPAG) will be 14.5% next year, following the recent announcement of the UK-US pharma trade agreement. That is a big reduction on the record 22.5% due from pharma manufacturers…
The American Hospital Association and several large hospital systems have filed a lawsuit seeking to halt an upcoming pilot program that would alter payments for medicines purchased through a controversial federal drug discount program. At issue is the 340B discount program, which was created to help hospitals and clinics care for low-income and rural patients….
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. WASHINGTON — The United States and United Kingdom announced a high-level agreement Monday under which the U.K. is expected to pay more for medicines. In exchange for agreeing to increase payments going forward, the U.K. will…
The Centers for Medicare and Medicaid Services (CMS) has revealed the prices for the second batch of 15 drugs going through Medicare’s negotiation process, promising a 44% cut that will save around $12 billion on the products. The new maximum fair prices (MFPs), due to come into effect on 1st January 2027, will bring down…
From Launch to Leadership: Mounjaro Crosses Rs 333 Crore, Becomes India’s Top-Selling Drug We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link